BioCentury
ARTICLE | Company News

Ultragenyx, Takeda in deal for rare genetic diseases

June 8, 2016 1:06 AM UTC

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to develop and commercialize therapies to treat rare genetic diseases.

Ultragenyx will receive an exclusive license to an undisclosed preclinical Takeda candidate in a pre-determined "field of use," and will have an exclusive option to co-develop and co-commercialize the candidate in additional therapeutic areas. Additionally, Ultragenyx may opt to obtain worldwide rights to up to five additional Takeda candidates for rare diseases under a five-year research collaboration between the companies. Takeda will have an exclusive option to commercialize any of the candidates in Asia. ...